Zobrazeno 1 - 10
of 513
pro vyhledávání: '"Janet, Fricker"'
Autor:
Fricker, Janet
Publikováno v:
Molecular Oncology; Dec2007, Vol. 1 Issue 3, p258-262, 5p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michael A. Gow
Publikováno v:
Contemporary Hypnosis. 22:115-119
Autor:
Fricker J
Publikováno v:
Molecular oncology [Mol Oncol] 2007 Dec; Vol. 1 (3), pp. 258-62.
Autor:
Janet Fricker
Publikováno v:
EMJ Dermatology. :2-11
Prof Elke de Jong focussed her presentation on data from randomised clinical trials (RCT) and real-world evidence (RWE) from psoriasis patient registries. Such data is complementary with RCT having high internal validity but low external validity, an
Autor:
Janet Fricker
Publikováno v:
EMJ Gastroenterology. :2-11
Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2). The data demonstrate that ustekinumab shows higher efficacy in patient
Autor:
Janet Fricker
Publikováno v:
EMJ Hematology. :2-12
Prof Salles provided an update on the ongoing first-line follicular lymphoma (FL) studies, demonstrating how analysis of the GALLIUM study data regarding the use of different chemotherapy backbones consistently showed the benefits of obinutuzumab (G)
Autor:
Janet Fricker
Publikováno v:
EMJ Dermatology. :2-6
This presentation by Dr Weisenseel considered the role of fumaric acid esters (FAE) in plaque psoriasis. FAE, first developed in 1959 and approved in 1994, are available in two forms: dimethyl fumarate (DMF) alone (e.g. Skilarence®; Almirall Ltd., U
Autor:
Janet Fricker
Publikováno v:
EMJ Respiratory. :38-46
With new patient-centric and scientific networks being created, Prof Chorostowska-Wynimko explored how these initiatives, such as the European Alpha-1 Research Collaboration (EARCO) and the European Reference Network-LUNG Alpha1 Antitrypsin Deficienc
Autor:
Janet Fricker
Publikováno v:
EMJ Cardiology. :38-46
Prof Masana presented evidence that low-density lipoprotein (LDL) cholesterol is a causal factor for atherosclerosis and that cardiovascular disease (CVD)-relative risk (RR) is reduced proportionally to LDL reductions, regardless of the type of monot